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Abstract
Background: Neonatal hypoglycaemia is common, affecting up to 15 % of newborn babies and 50 % of those
with risk factors (preterm, infant of a diabetic, high or low birthweight). Hypoglycaemia can cause brain damage
and death, and babies born at risk have an increased risk of developmental delay in later life.
Treatment of hypoglycaemia usually involves additional feeding, often with infant formula, and admission to
Neonatal Intensive Care for intravenous dextrose. This can be costly and inhibit the establishment of breast feeding.
Prevention of neonatal hypoglycaemia would be desirable, but there are currently no strategies, beyond early
feeding, for prevention of neonatal hypoglycaemia. Buccal dextrose gel is safe and effective in treatment of
hypoglycaemia. The aim of this trial is to determine whether 40 % dextrose gel given to babies at risk prevents
neonatal hypoglycaemia and hence reduces admission to Neonatal Intensive Care.
Methods/design: Design: Randomised, multicentre, placebo controlled trial.
Inclusion criteria: Babies at risk of hypoglycaemia (preterm, infant of a diabetic, small or large), less than 1 h old,
with no apparent indication for Neonatal Intensive Care Unit admission and mother intends to breastfeed.
Trial entry & randomisation: Eligible babies of consenting parents will be allocated by online randomisation to the
dextrose gel group or placebo group, using a study number and corresponding trial intervention pack.
Study groups: Babies will receive a single dose of 0.5 ml/kg study gel at 1 h after birth; either 40 % dextrose gel
(200 mg/kg) or 2 % hydroxymethylcellulose placebo. Gel will be massaged into the buccal mucosal and followed
by a breast feed.
Primary study outcome: Admission to Neonatal Intensive Care.
Sample size: 2,129 babies are required to detect a decrease in admission to Neonatal Intensive Care from 10–6 %
(two-sided alpha 0.05, 90 % power, 5 % drop-out rate).
Discussion: This study will investigate whether admission to Neonatal Intensive Care can be prevented by
prophylactic oral dextrose gel; a simple, cheap and painless intervention that requires no special expertise or
equipment and hence is applicable in almost any birth setting.
Trial registration: Australian New Zealand Clinical Trials Registry - ACTRN 12614001263684.
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Background
Significance of the project
Neonatal hypoglycaemia is common in the first few
days after birth. Up to 15 % of normal newborn ba-
bies will have low blood glucose concentrations [1].
However, the incidence in babies who have risk fac-
tors is much greater: up to 50 % in infants of diabetic
mothers, [2] large and small babies [3] and 66 % in
preterm babies [4].
Glucose is the primary energy source for the brain,
and neonatal hypoglycaemia is associated with brain
damage and death [4–6]. Babies born at risk for neonatal
hypoglycaemia have an increased risk of developmental
delay in later life [7–10]. Indeed, it has been reported
that neonatal hypoglycaemia is the only neonatal mor-
bidity independently associated with later developmental
delay in late preterm babies [11]. While it is uncertain
what degree or duration of hypoglycaemia is necessary
before morbidity occurs, it is known that even babies
without symptoms can have adverse outcomes [4, 6].
Thus hypoglycaemia is common and the only readily
preventable cause of brain damage in the newborn.
Standard management
Blood glucose concentrations normally fall in the first
1–2 h after birth, and then begin to rise again as babies
mobilise their body stores of fat and glycogen and begin
to feed. In some babies, this physiological fall in blood
glucose concentration may persist and, if untreated, po-
tentially may cause permanent brain damage. Since
hypoglycaemia is often asymptomatic, the recom-
mended approach is to monitor blood glucose con-
centrations in all babies at risk, usually by repeated
heel-prick blood samples, commonly 4 hourly, in the
first 1–2 days [12, 13]. This is painful for the baby
and distressing for all concerned.
It is generally accepted that blood glucose concentra-
tions < 2.6 mmol/L require treatment [4, 14, 15]. Stand-
ard management of babies in whom low glucose
concentrations are detected is to minimise the duration
of hypoglycaemia and ensure the glucose is ‘normalised’
as quickly as possible [6, 16]. This commonly requires
admission to Neonatal Intensive Care Unit (NICU) for
intravenous glucose, separating mother and baby and
delaying the establishment of breast feeding as well as
incurring high healthcare costs.
The American Academy of Pediatrics advises early
identification of the at-risk baby and institution of
prophylactic measures to prevent neonatal hypoglycaemia
[12]. This is commonly achieved by early feeding, often
with supplemental formula milk [12, 17]. However, sup-
plementing with formula milk has been shown to reduce
longer term breastfeeding rates [18]. Furthermore, there
are both human and experimental data indicating that
supplementation of newborns in the first two weeks may
have long-term effects on metabolic outcomes. Even brief
periods of nutritional supplementation in preterm babies
result in altered control of blood pressure and insulin
regulation in adolescence [19, 20]. Thus, interventions
that prevent hypoglycaemia without supplemental, artifi-
cial feeds may help maintain breastfeeding and also have




Harris et al. demonstrated that treatment of neonatal
hypoglycaemia with oral dextrose gel was more effective
than feeding alone in reversing the hypoglycaemia, and
also reduced the rate of NICU admission for this prob-
lem and reduced the rate of formula feeding at two
weeks of age [21]. Importantly, the gel was well-
tolerated, cheap, simple and safe to administer, and was
acceptable to families and caregivers.
Aim
We therefore propose a randomised controlled trial to
determine if prophylactic oral dextrose gel given to new-
borns at risk prevents neonatal hypoglycaemia and thus
reduces NICU admission, improves breast feeding rates
and reduces costs as well as potentially reducing the risk
of later adverse outcomes.
Hypothesis
The primary hypothesis of this study is that, compared
to placebo and standard care, prophylactic 40 % oral
dextrose gel given to babies at risk of hypoglycaemia (in-
fant of diabetic mother, preterm, large or small for dates,




Ethics approval has been obtained from the Health and
Disability Ethics Committees of New Zealand (ethics ref-
erence 13/NTA/8) and by the local institutional research
review committees for each centre. The ethics commit-
tee is notified of any amendments to the study protocol.
Study design
A multicentre, randomised, placebo controlled trial com-
paring 40 % dextrose gel with placebo to prevent
hypoglycaemia in the first 48 h in babies born at risk.
Study population
Inclusion criteria
Babies born at risk of hypoglycaemia, defined as satisfy-
ing at least ONE of the following:
Harding et al. BMC Pediatrics  (2015) 15:120 Page 2 of 5
1. Infants of diabetic mothers (any type of diabetes)
2. Preterm (< 37 weeks’ gestation)
3. Small (< 2.5 kg or < 10th centile on population or
customised birthweight chart)
4. Large (> 4.5 kg or > 90th centile on population or
customised birthweight chart)
AND satisfy ALL of the following:
1. ≥ 35 weeks’ gestation
2. Birth-weight ≥ 2.2 kg
3. < 1 h old
4. No apparent indication for NICU admission at time
of randomisation
5. Unlikely to require admission to NICU for any other
reasons e.g. respiratory distress
6. Mother intending to breast-feed
Exclusion criteria
1. Major congenital abnormality
2. Previous formula feed or intravenous fluids
3. Previous diagnosis of hypoglycaemia
4. Admitted to NICU
5. Imminent admission to NICU.
Primary outcome
Admission to NICU
This is defined as admission to NICU (or Special Care
Baby Unit (SCBU) for the hospitals which use that
name) for > 4 h [22].
Secondary outcomes
1. Hypoglycaemia (any blood glucose concentration <
2.6 mmol/L in the first 48 h);
2. Admission to NICU for hypoglycaemia;
3. Hyperglycaemia (any blood glucose concentration >
10 mmol/L);
4. Breastfeeding at discharge from hospital (full or
exclusive);
5. Received any formula prior to discharge from
hospital;
6. Formula feeding at 6 weeks of age;
7. Cost of care until primary discharge home;
8. Maternal satisfaction (via telephone questionnaire at
6 weeks);
9. Neurosensory disability at 2 years’ corrected age
(any of: legal blindness; sensorineural deafness
requiring hearing aids; cerebral palsy; Bayley
Scale of Infant Development Version III
cognitive, language or motor score lower




Parents of babies who are likely to become eligible
(maternal diabetes, likely late preterm birth, or antici-
pated high or low birth weight) will be identified
through lead maternity carers and antenatal clinics
and provided with an information sheet as early as is
feasible. Written informed consent will normally be
obtained before the birth.
Randomisation
Eligible babies for whom consent has been obtained will
be enrolled and randomised immediately after birth. Ba-
bies will be assigned randomly via an internet random-
isation service to the dextrose or placebo group with
priority stratification for collaborating centre and risk
factor (i.e. maternal diabetes, preterm, small or large).
Discontinuation of randomised treatment
The allocated treatment can be stopped at any time at
the request of the parents, or by the neonatologist caring
for the baby if (s) he feels that stopping the treatment
would be in the best interest of the baby. The baby will
still be followed up and analysed according to the
intention-to-treat principle.
Study groups
The study intervention drug (both dextrose gel and pla-
cebo) will be supplied by Biomed Ltd (Auckland, New
Zealand) in identically labelled, pre-filled syringes of ei-
ther 40 % dextrose gel or identical appearing 2 % hydro-
xymethylcellulose placebo gel in individually pre-labelled
trial packs. Each participating centre will have a supply
of study packs held in a medications fridge. The staff
member randomising the baby will receive a study num-
ber corresponding to a pre-labelled study pack, and also
the volume of gel (0.5 ml/kg) to be administered. The
inside of the baby’s cheek will be dried with a gauze
swab, and the study gel massaged into the buccal mu-
cosa at one hour after birth.
In order to determine the most effective dose in pre-
vention of neonatal hypoglycaemia, we undertook a dos-
age trial (registered with the Australian New Zealand
Clinical Trials Registry ACTRN12613000322730). The
dose selected of 0.5 ml/kg (200 mg/kg) 40 % dextrose
gel at 1 h of age had maximal efficacy in prevention of
hypoglycaemia, with the fewest limitations (i.e. was easy
to administer, well tolerated and with minimal additional
workload or financial cost).
Blood glucose analysis
The initial blood glucose concentration will be measured
at 2 h, as is common practice. Subsequent management
will be according to hospital standard practices. All
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blood glucose concentrations will be analysed by the
gold standard glucose oxidase method, either with a
portable blood glucose analyser (e.g. iSTAT, Abbott La-
boratories, Abbott Park, IL USA) or a combined metab-
olite/blood gas analyser (e.g. ABL 700, Radiometer Ltd,
Copenhagen, Denmark).
Follow up after birth until time of discharge from
hospital
Surveillance
Babies will be monitored according to routine clinical
practice. This includes pre-feed blood glucose measure-
ments 2–4 hourly for at least the first 12 h, and until
there have been 3 consecutive measurements >
2.6 mmol/L. If the baby becomes hypoglycaemic (blood
glucose concentration < 2.6 mmol/L) then the hospital
protocol will be followed for management of
hypoglycaemia, including the administration of treat-
ment dextrose gel and supplementary feeds if relevant.
We will monitor for serious adverse events (seizures and
death) and other adverse events; hyperglycaemia (as
above), late hypoglycaemia (blood glucose concentration
< 2.6 mmol/L for the first time after 12 h of age), delayed
feeding (failure to establish breastfeeding without sup-
plements by the end of day 3) and systemic sepsis [22].
Follow-up after primary hospitalisation
Parent (s) of participants will be contacted on day 3
(if already discharged home) and 6 weeks after birth
to complete a telephone questionnaire. This will in-
clude details of the current feeding regime, and at
6 weeks, parental satisfaction with participation in the
trial and health status of the baby. We will maintain
contact with babies and their families. At 2 years’ cor-
rected age all families will be contacted to arrange a
developmental assessment to investigate longer-term
outcomes. We will provide results when available to
those who have informed us that they wish to be
made aware of the outcome of the trial.
Data analysis
The primary outcome of NICU admission will be ana-
lysed by logistic regression, stratifying by collaborating
centre. Secondary analyses will adjust for potentially
confounding variables: reason for risk of hypoglycaemia
(infant of diabetic, late preterm, small or large), sex, ges-
tational age, and mode of birth (vaginal vs caesarean sec-
tion). Continuous data will be compared by Student’s t
test, or the Mann–Whitney U test if the data are not
normally distributed and cannot be converted to near-
normality by simple transformation. Data with repeated
points, such as blood glucose concentrations, will be
compared using mixed model techniques, modelling the
main effect of treatment group allocation, time and their
interaction, with significant main effects and interactions
tested using the method of Tukey. All tests will be two-
tailed, with P < 0.05 considered significant. The data will
be analysed on an intention-to-treat basis, and any baby
who dies or for whom the primary outcome of NICU
admission cannot be determined will be assigned the
worst case outcome of NICU admission.
Economic evaluation
The cost-effectiveness of oral dextrose gel to prevent
neonatal hypoglycaemia will be compared with usual
care (no prophylaxis) within the period to discharge.
Intervention costs: A per-baby cost of dextrose gel will
be based on the cost of the gel syringes and dispensing
costs. For the no prophylaxis option, a zero intervention
cost will be assumed.
Other Hospital Costs: Resource utilisation will be ob-
tained from a clinical record form identifying both
length of stay (LOS) and relevant Diagnostic Related
Group (DRG) code for the mother, plus any subsequent
operative procedure (DRG), respiratory problem requir-
ing treatment (DRG), and NICU admission for the baby
(plus LOS). Costs will be assessed using New Zealand
Ministry of Health cost weights and purchase unit
prices. For the no prophylaxis option, the costs from the
placebo gel arm will be used.
Cost-effectiveness will be assessed using incremental
cost-effectiveness ratios (ICERs) formed in terms of an
incremental cost per case of hypoglycaemia avoided. Un-
certainty in these figures will be assessed using non-
parametric bootstrapping (sampling with replacement)
to form a distribution for the ICER, potentially including
corrections for any differences in the composition of the
trial arms in any confounding factors. This analysis will
be presented using cost-effectiveness acceptability curves
that identify the likelihood of each option being cost-
effective for different values attached to reducing a case
of hypoglycaemia.
Power and sample size
Based on data from Auckland City Hospital and Waikato
Hospital, 10 % of at-risk babies will require admission to
NICU. A trial of 2,129 babies (1,014 in each arm, with
continuity correction and allowing for 5 % drop-out rate),
will have 90 % power to detect a 40 % relative reduction
(absolute reduction of 4 %) in admission to NICU from
10–6 % with two-sided alpha of 0.05.
Should this study show that dextrose gel is effective at
preventing NICU admission, it will be critical to find out
if this also improves long-term outcomes for babies. A
sample size of 2,014 babies would allow us to detect a
reduction in the number of children with one or more
low developmental scores (<1SD below the mean) on a
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Bayley Infant Scales of Development Edition III assess-
ment at 2 years from 40–33 %.
Discussion
This study is the first to investigate whether neonatal
hypoglycaemia and admission to NICU can be prevented
by oral dextrose gel, a simple, cheap and painless inter-
vention. This intervention requires no special expertise
or equipment and hence is applicable in almost any birth
setting. Reduction of admission to NICU will reduce
separation of mother and baby, and may improve breast-
feeding rates and reduce financial cost.
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